Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage are …

Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …

With the potential development of new disease-modifying Alzheimer’s disease (AD) therapies,
simple, widely available screening tests are needed to identify which individuals, who are …

Background The cerebrospinal fluid (CSF) biomarkers amyloid beta 1–42, total tau, and
phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient …

Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in
blood samples, and has been associated with Alzheimer’s disease (AD). However, plasma …

Biomarkers in body fluids could help to predict and monitor neurological decline in people
with multiple sclerosis (MS). We discuss markers for axonal damage in body fluids in people …

In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …

Background Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau
phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau pathology. …